 Tree MATA MPL is designed to provide a vaccine that will be efficacious with only three escalating dose injections, in contrast to the longer schedules currently in use. It is designed to have all of the current advantages of an allergy vaccine, which can modify the underlying disease process, as opposed to pharmacological control, which treats only the symptoms. The vaccine will also be safer to use than a formulation containing a similar mass of unmodified allergen extract due to the propensity of the unmodified allergen extract to cause severe local allergic reactions or anaphylaxis, because of its reduced reactivity with IgE antibody. 